Current Affairs - Science - Discussion

Zydus has introduced an affordable Semaglutide injection in India, targeting the treatment of Type 2 Diabetes Mellitus and obesity. The innovation includes a reusable multi-dose pen, allowing patients to adjust dosages conveniently from a single device, unlike traditional single-use pens. This significantly improves ease of use and reduces treatment costs, with an average monthly expense of around ₹2,200. Manufactured at the Zydus Biotech Park in Ahmedabad, the product aims to make GLP-1 therapies more accessible, especially in a country facing a growing burden of diabetes and rising obesity rates.